Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LIFE

Atyr Pharma Inc

May 06 • 04:00PM ET

1.66

Dollar change +0.05
Percentage change 3.11	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAT DFUS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.90	Insider Own	3.09%	Shs Outstand	69.01M	Perf Week	3.75%
Market Cap	114.56M	Forward P/E	-	EPS next Y	-0.75	Insider Trans	1.35%	Shs Float	66.88M	Perf Month	-10.75%
Income	-53.93M	PEG	-	EPS next Q	-0.23	Inst Own	59.65%	Short Float	0.57%	Perf Quarter	-2.35%
Sales	0.59M	P/S	194.16	EPS this Y	2.39%	Inst Trans	0.60%	Short Ratio	0.67	Perf Half Y	28.68%
Book/sh	1.24	P/B	1.34	EPS next Y	18.53%	ROA	-43.13%	Short Interest	0.38M	Perf Year	-19.02%
Cash/sh	1.22	P/C	1.36	EPS next 5Y	13.00%	ROE	-55.50%	52W Range	1.08 - 2.70	Perf YTD	17.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.36%	ROI	-55.34%	52W High	-38.52%	Beta	1.17
Dividend TTM	-	Quick Ratio	6.07	Sales past 5Y	436.18%	Gross Margin	-368.71%	52W Low	53.69%	ATR (14)	0.09
Dividend Ex-Date	-	Current Ratio	6.07	EPS Y/Y TTM	37.64%	Oper. Margin	-9994.56%	RSI (14)	48.07	Volatility	4.68% 5.07%
Employees	59	Debt/Eq	0.17	Sales Y/Y TTM	-94.34%	Profit Margin	-9171.60%	Recom	1.00	Target Price	25.25
Option/Short	Yes / Yes	LT Debt/Eq	0.15	EPS Q/Q	17.81%	Payout	-	Rel Volume	2.31	Prev Close	1.61
Sales Surprise	540.33%	EPS Surprise	8.00%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	572.67K	Price	1.66
SMA20	0.80%	SMA50	-6.16%	SMA200	3.15%	Trades		Volume	1,323,181	Change	3.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-05-23	Downgrade	Oppenheimer	Outperform → Perform
Oct-12-21	Initiated	RBC Capital Mkts	Outperform	$22
Sep-21-21	Initiated	Piper Sandler	Overweight	$19
May-10-21	Initiated	Laidlaw	Buy	$18
Aug-17-20	Upgrade	H.C. Wainwright	Neutral → Buy	$13
Mar-04-20	Initiated	ROTH Capital	Buy	$15
Mar-02-20	Initiated	Oppenheimer	Outperform	$8
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-07-17	Initiated	Piper Jaffray	Overweight	$7
Dec-13-16	Downgrade	JP Morgan	Overweight → Neutral
Dec-16-15	Initiated	Citigroup	Neutral
Jun-01-15	Initiated	JP Morgan	Overweight	$44
Jun-01-15	Initiated	Citigroup	Buy	$32

Show Previous Ratings

Today 08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
May-02-24 09:58PM	LIFE Stock Earnings: aTyr Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:15PM	Atyr Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update (GlobeNewswire)
Apr-01-24 08:00AM	aTyr Pharma to Participate in April Investor Conferences (GlobeNewswire)
02:19PM	Loading…
Mar-26-24 02:19PM	3 Penny Stocks That Could Be Multibaggers in the Making: March Edition (InvestorPlace)
Mar-15-24 01:33PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript (Insider Monkey) +22.84%
11:30AM	Q4 2023 aTyr Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
11:01AM	aTyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress (GuruFocus.com)
Mar-14-24 08:56PM	LIFE Stock Earnings: aTyr Pharma Misses EPS for Q4 2023 (InvestorPlace)
04:16PM	Atyr Pharma: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update (GlobeNewswire)
Feb-28-24 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results (GlobeNewswire) -5.00%
Feb-21-24 08:00AM	aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants (GlobeNewswire)
Jan-29-24 08:00AM	aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity (GlobeNewswire)
08:00AM	Loading…
Jan-18-24 08:00AM	aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor (GlobeNewswire)
Nov-13-23 08:00AM	aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023 (GlobeNewswire)
Nov-09-23 04:07PM	Atyr Pharma: Q3 Earnings Snapshot (Associated Press Finance) -5.74%
04:00PM	aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Nov-01-23 08:00AM	aTyr Pharma to Present at November Investor Conferences (GlobeNewswire)
Oct-31-23 08:00AM	aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD (GlobeNewswire)
Sep-11-23 08:00AM	aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes (GlobeNewswire)
Aug-30-23 09:35AM	Down -9.64% in 4 Weeks, Here's Why You Should You Buy the Dip in Atyr Pharma (LIFE) (Zacks)
Aug-24-23 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-09-23 05:30PM	Atyr Pharma (LIFE) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Atyr Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
Jul-20-23 07:30AM	aTyr Pharma, Inc. (NASDAQ:LIFE) is a favorite amongst institutional investors who own 56% (Simply Wall St.)
Jun-28-23 07:00AM	7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023 (InvestorPlace)
Jun-22-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Systemic Sclerosis (GlobeNewswire)
08:00AM	Loading…
Jun-20-23 08:00AM	aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference (GlobeNewswire)
Jun-09-23 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-23 08:00AM	aTyr Pharma to Highlight Advancements in tRNA Synthetase Biology Research at the 13th International Symposium of Aminoacyl-tRNA Synthetases (AARS 2023) (GlobeNewswire)
May-25-23 08:00AM	aTyr Pharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-22-23 08:00AM	aTyr Pharma Presents New Data on Efzofitimod Mechanism of Action and Positive Exposure-Response at the American Thoracic Society 2023 International Conference (GlobeNewswire)
07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com)
May-13-23 08:06AM	aTyr Pharma Independent Director Acquires 25% More Stock \ (Simply Wall St.)
May-11-23 04:00PM	aTyr Pharma to Present at the 2023 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-10-23 06:11AM	aTyr Pharma (NASDAQ:LIFE) investors are sitting on a loss of 89% if they invested five years ago (Simply Wall St.) +6.10%
May-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:12PM	Atyr Pharma: Q1 Earnings Snapshot (AP Finance)
04:00PM	aTyr Pharma Announces First Quarter 2023 Results and Provides Corporate Update (GlobeNewswire)
May-07-23 04:00AM	3 Stocks and Cryptos With the Highest Potential Returns (InvestorPlace)
May-05-23 02:24PM	7 Hot Growth Stocks Poised to Triple in 2023 (InvestorPlace)
Apr-17-23 08:00AM	aTyr Pharma Presents Preclinical Research Demonstrating Treatment with ATYR2810 Inhibits Tumor Growth and Therapy Resistance in Highly Aggressive Cancers at the 2023 AACR Annual Meeting (GlobeNewswire)
Mar-30-23 08:00AM	aTyr Pharma Announces First Major Review Article for Efzofitimod Published in the Journal Sarcoidosis, Vasculitis and Diffuse Lung Diseases (GlobeNewswire)
Mar-28-23 10:45AM	2 Strong Buy Penny Stocks With Over 200% Upside on the Horizon (TipRanks) +9.64%
Mar-23-23 07:10AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
Mar-21-23 08:00AM	aTyr Pharma to Present Data Identifying Fibrosis Target for tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis Pathogenesis and Resolution (GlobeNewswire)
Mar-20-23 08:00AM	aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies (GlobeNewswire)
Mar-09-23 05:15PM	Atyr Pharma (LIFE) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -9.18%
04:00PM	aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update (GlobeNewswire)
Mar-08-23 08:00AM	aTyr Pharma to Present at March Investor Conferences (GlobeNewswire)
Mar-02-23 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2022 Financial Results (GlobeNewswire)
Mar-01-23 08:00AM	aTyr Pharma Announces Phase 2 Study of Efzofitimod in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Following FDA Clearance of IND Application (GlobeNewswire)
Feb-17-23 12:00PM	Atyr Pharma (LIFE) Upgraded to Buy: Here's What You Should Know (Zacks)
Feb-10-23 05:21AM	With 37% stake, aTyr Pharma, Inc. (NASDAQ:LIFE) seems to have captured institutional investors' interest (Simply Wall St.)
Feb-09-23 08:00AM	aTyr Pharma Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.56%
Feb-08-23 04:11PM	aTyr Pharma Announces Commencement of Public Offering of Common Stock (GlobeNewswire)
Feb-06-23 08:00AM	aTyr Pharma Announces Achievement of Development Milestone by Partner Kyorin Pharmaceutical, Co., Ltd. (GlobeNewswire) +6.52%
Jan-31-23 08:00AM	aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference (GlobeNewswire)
Jan-19-23 08:00AM	aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis (GlobeNewswire)
Jan-18-23 08:00AM	European Commission Grants Orphan Drug Designation for aTyr Pharmas Efzofitimod for Treatment of Sarcoidosis (GlobeNewswire)
Dec-29-22 06:59PM	aTyr Pharma, Inc. (NASDAQ:LIFE) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-15-22 08:00AM	aTyr Pharma Announces LTBP1 as Target of DARS tRNA Synthetase Fragment (GlobeNewswire)
Nov-18-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-10-22 05:15PM	Atyr Pharma (LIFE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:00PM	aTyr Pharma Announces Third Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-09-22 08:00AM	aTyr Pharma Announces Publication of Positive Data from Phase 1b/2a Clinical Study of Efzofitimod for the Treatment of Pulmonary Sarcoidosis in the Journal CHEST (GlobeNewswire)
Nov-03-22 08:02AM	aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-25-22 08:00AM	aTyr Pharma to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-11-22 08:00AM	aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets (GlobeNewswire)
Oct-04-22 08:00AM	aTyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium (GlobeNewswire) +6.64%
Sep-29-22 08:00AM	aTyr Pharma Announces Notice of Allowance for U.S. Patent for Anti-Neuropilin-2 (NRP2) Monoclonal Antibodies (GlobeNewswire)
Sep-27-22 08:00AM	aTyr Pharma Announces Dosing of First Patient in Pivotal Phase 3 EFZO-FIT Study of Efzofitimod in Patients with Pulmonary Sarcoidosis (GlobeNewswire)
Sep-16-22 08:35AM	Life Sciences Virtual Investor Conference: Presentations Now Available for On-Demand Viewing (GlobeNewswire) -6.73%
Sep-13-22 08:00AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod for Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) (GlobeNewswire)
Sep-12-22 08:35AM	Life Sciences Virtual Investor Conference Agenda Announced for September 15th (GlobeNewswire)
Sep-09-22 11:52AM	Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation (Simply Wall St.)
08:00AM	aTyr Pharma to Present at the Life Sciences Investor Forum on September 15th (GlobeNewswire)
Sep-06-22 08:00AM	aTyr Pharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference 2022 (GlobeNewswire)
Sep-01-22 08:00AM	aTyr Pharma to Present Poster at the European Respiratory Society (ERS) International Congress 2022 (GlobeNewswire)
Aug-15-22 04:00PM	aTyr Pharma Announces Second Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
Aug-12-22 04:05PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-11-22 08:03AM	aTyr Pharma Receives FDA Fast Track Designation for Efzofitimod (ATYR1923) for Treatment of Pulmonary Sarcoidosis (GlobeNewswire)
Aug-04-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-24-22 02:22PM	Bullish aTyr Pharma, Inc. (NASDAQ:LIFE) insiders filled their treasuries with US$2.1m worth of stock over last year (Simply Wall St.)
Jun-14-22 08:00AM	aTyr Pharma Announces FGFR4 as Receptor Target for AARS tRNA Synthetase Fragment (GlobeNewswire)
Jun-13-22 08:00AM	aTyr Pharma to Present Findings from its tRNA Synthetase Platform at the International 28th tRNA Conference (GlobeNewswire) -6.03%
Jun-01-22 08:00AM	aTyr Pharma to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 08:00AM	aTyr Pharma Presents Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference (GlobeNewswire)
May-16-22 08:00AM	aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis (GlobeNewswire)
May-13-22 04:00PM	aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-22 02:00PM	Is aTyr Pharma, Inc. (NASDAQ:LIFE) Popular Amongst Institutions? (Simply Wall St.)
08:00AM	aTyr Pharma to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-22 05:15PM	Atyr Pharma (LIFE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.07%
04:00PM	aTyr Pharma Announces First Quarter 2022 Results and Provides Corporate Update (GlobeNewswire)
02:40AM	Love Hemp Group PLC Announces Update Regarding Trading Suspension (ACCESSWIRE)
May-02-22 08:00AM	aTyr Pharma to Webcast Conference Call Reporting First Quarter 2022 Financial Results (GlobeNewswire)

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Broadfoot Jill Marie	Chief Financial Officer	Feb 06 '24	Sale	1.69	1,590	2,687	20,821	Feb 06 08:18 PM
Shukla Sanjay	President and CEO	Dec 12 '23	Buy	1.18	12,000	14,136	106,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Dec 11 '23	Buy	1.17	3,000	3,510	94,173	Dec 12 06:50 PM
Shukla Sanjay	President and CEO	Nov 13 '23	Buy	1.11	13,578	15,085	91,173	Nov 13 04:11 PM
Shukla Sanjay	President and CEO	Nov 10 '23	Buy	1.14	1,422	1,618	77,595	Nov 13 04:11 PM
Shukla Sanjay	President and CEO	Jul 28 '23	Buy	2.01	15,000	30,224	76,173	Aug 01 04:07 PM
SCHIMMEL PAUL	Director	May 10 '23	Buy	2.25	200,000	450,000	313,023	May 11 09:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIFE

Atyr Pharma Inc

Upgrade your FINVIZ experience